{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:35:27Z","timestamp":1783532127602,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3191,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004201","name":"Oncosuisse","doi-asserted-by":"crossref","award":["ICP OCS-02062-03-2007"],"award-info":[{"award-number":["ICP OCS-02062-03-2007"]}],"id":[{"id":"10.13039\/501100004201","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Johnson-Cilag AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1093\/annonc\/mdq416","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T01:44:42Z","timestamp":1283391882000},"page":"689-695","source":"Crossref","is-referenced-by-count":60,"title":["Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)"],"prefix":"10.1016","volume":"22","author":[{"given":"A.","family":"Conconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopez-Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rigacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Devizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq416_bb0010","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"214","article-title":"Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","author":"Isaacson","year":"2008"},{"key":"10.1093\/annonc\/mdq416_bb0015","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1200\/JCO.2005.05.018","article-title":"State-of-the-art therapeutics: marginal-zone lymphoma","volume":"23","author":"Bertoni","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0020","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq416_bb0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","author":"Ferreri","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0030","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq416_bb0035","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0040","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdq416_bb0045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","article-title":"Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial","volume":"144","author":"Hancock","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq416_bb0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.743","article-title":"Radiation therapy for localized low-grade non-Hodgkin's lymphomas","volume":"23","author":"Tsang","year":"2005","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0055","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdl126","article-title":"Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial","volume":"17","author":"Jager","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0060","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cncr.20237","article-title":"Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma","volume":"100","author":"Zinzani","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq416_bb0065","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq416_bb0070","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0075","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21414","article-title":"Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies","volume":"104","author":"Ludwig","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq416_bb0080","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0090","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","article-title":"Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0095","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0105","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq416_bb0110","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/cncr.24518","article-title":"Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)","volume":"115","author":"Ribrag","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq416_bb0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq416_bb0120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdq416_bb0130","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/cncr.20182","article-title":"Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies","volume":"100","author":"Panwalkar","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq416_bb0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/JCI27476","article-title":"Delving deeper into MALT lymphoma biology","volume":"116","author":"Bertoni","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdq416_bb0140","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq416_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdq416_bb0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0155","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq416_bb0160","article-title":"Common Toxicity Criteria Manual (PDF)","year":"1999","journal-title":"Reference document based on the CTC v2.0"},{"key":"10.1093\/annonc\/mdq416_bb0165","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0170","series-title":"Extranodal Lymphomas Pathology and Management","first-page":"114","article-title":"MALT lymphoma pathology, initial diagnosis, and posttreatment evaluation","author":"Copie-Bergman","year":"2008"},{"key":"10.1093\/annonc\/mdq416_bb0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/bjc.1995.364","article-title":"Review of survival analyses published in cancer journals","volume":"72","author":"Altman","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq416_bb0180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdq416_bb0185","series-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"10.1093\/annonc\/mdq416_bb0190","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2008.001537","article-title":"A phase II study of bortezomib in patients with MALT lymphoma","volume":"94","author":"Troch","year":"2009","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq416_bb0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","author":"Di Bella","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq416_bb0200","doi-asserted-by":"crossref","first-page":"33713","DOI":"10.1074\/jbc.R109.018481","article-title":"The 26 S proteasome: from basic mechanisms to drug targeting","volume":"284","author":"Navon","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdq416_bb0205","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"de Vos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq416_bb0210","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2141.2009.07775.x","article-title":"Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma","volume":"146","author":"Gerecitano","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq416_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.2009.07836.x","article-title":"Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"147","author":"Barr","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq416_bb0220","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1158\/1078-0432.CCR-05-0308","article-title":"The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide","volume":"12","author":"O'Connor","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq416_bb0225","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1158\/1078-0432.CCR-08-2365","article-title":"PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells","volume":"15","author":"Bhalla","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419386132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/3\/689\/719300\/mdq416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:26:42Z","timestamp":1624699602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419386132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0923753419386132"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq416","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}